GLAND PHARMA LIMITED

August 5, 2026

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Press Release - Gland Pharma and Neuland Laboratories Announce Strategic Collaboration for Sterile API Manufacturing

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; please find attached announcement regarding ***Strategic Collaboration for Sterile API Manufacturing with Neuland Laboratories.***

This is for your information and records.

Yours truly,

For Gland Pharma Limited

Pallerlamudi Sampath Kumar

Digitally signed by Pallerlamudi Sampath Kumar
DN: cn=Pallerlamudi Sampath Kumar, c=IN, o=Personal, email=sampath@glandpharma.com
Date: 2026.08.05 15:53:41 +05'30'

Sampath Kumar Pallerlamudi
Company Secretary & Compliance Officer

Encl: As above

Gland Pharma and Neuland Laboratories Announce Strategic Collaboration for Sterile API Manufacturing

Partnership to expand sterile API manufacturing through a new, cGMP state-of-the-art sterile suite

Hyderabad, India, 5th August 2026 – Gland Pharma Limited ("Gland Pharma") and Neuland Laboratories Limited ("Neuland") today announced a long-term strategic CDMO partnership. Under the partnership Gland will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products. The collaboration combines Neuland's Complex API development and manufacturing capabilities including deep expertise in complex chemistry, process development, custom manufacturing having a strong track record of serving global innovator and generic pharmaceutical companies; with Gland Pharma's global sterile manufacturing expertise and strong regulatory compliance track record, to serve growing worldwide demand for sterile APIs used in microparticle depot products and other complex sterile APIs.

The collaboration represents a significant expansion of the relationship between the two companies, creating a dedicated manufacturing platform that aligns their complementary capabilities under a long-term strategic partnership. Under the collaboration, Gland Pharma will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility at Visakhapatnam to support Neuland for its growing demand of sterile APIs. The facility will be constructed and operated to cGMP, USFDA and EU standards, and will be backed by Gland Pharma's proven aseptic manufacturing expertise. Together, the companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs. The suite will be designed to add approximately 1400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth.

The partnership is expected to enhance supply resilience globally by combining Neuland's development and regulatory expertise with Gland Pharma's manufacturing capabilities.

Mr. Srinivas Sadu, Executive Chairman, Gland Pharma Limited, said:

"We are pleased to further strengthen our collaboration with Neuland through this strategic partnership. This investment expands our capabilities in sterile API manufacturing and supports increasing customer demand. By leveraging the complementary strengths of both organizations, we will provide a robust and scalable CDMO solution backed by world-class quality, compliance and manufacturing excellence. We believe this partnership creates a strong foundation for sustainable growth and long-term value creation for our customers and both organizations."

Mr. Saharsh Davuluri, CEO & MD, Neuland Laboratories Limited, said:

"Demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies. Through this partnership with Gland Pharma, we are combining Neuland's expertise in complex APIs with Gland's proven sterile manufacturing capabilities to create a differentiated platform for global customers. Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their CDMO partners."

About Gland Pharma Limited (BSE: 543245, NSE: GLAND)

Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and has an excellent track record in developing, manufacturing, and marketing sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. It also enjoys the distinction of having pioneered Heparin technology in India.

About Neuland Laboratories Limited (BSE: 524558, NSE: NEULANDLAB)

Neuland Laboratories Limited [Neuland] is a specialist API CDMO partner for big pharma and biotech – delivering world-class process development and commercial supply services for the most complex molecules and New Chemical Entities. Serving clients in over 80 countries, Neuland operates three US FDA and EU GMP-compliant facilities in India, with a combined reactor capacity of approximately 1218kL. The CDMO invested in a new commercial scale peptide facility in 2026, and is opening a large, dedicated R&D process development centre in Hyderabad. The company has filed over 1000 DMFs globally – as it also supports generic drug substance providers – and offers more than 100 APIs across multiple therapeutic areas.